[ASA and clopidogrel for urological operations. Perioperative management]. / ASS und Clopidogrel bei urologischen Operationen. Perioperatives management.
Urologe A
; 52(11): 1597-605, 2013 Nov.
Article
em De
| MEDLINE
| ID: mdl-24121474
ABSTRACT
In a systematic overview and meta-analysis among more than 50,000 patients at risk for coronary artery disease, not adhering to or discontinuing aspirin (acetylsalicylic acid, ASA) was associated with a significantly increased risk of non-fatal myocardial infarction or death. Withdrawal of low dose aspirin was correlated with a threefold increase in the risk of adverse cardiovascular events. This risk is present irrespective of the length of time patients had been taking low dose aspirin. Therefore, in patients on chronic low dose aspirin for secondary prevention of cardiovascular disease, aspirin should never be discontinued. In the few available studies in urological surgery the increase in bleeding does not translate into a significant increase in specific morbidity. This seems to be also true for the additional administration of clopidogrel to aspirin. Nevertheless, in patients with drug-eluting stents and dual antiplatelet therapy, urologists should ensure a multidisciplinary management of the perioperative course.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Procedimentos Cirúrgicos Urológicos
/
Ticlopidina
/
Doenças Cardiovasculares
/
Aspirina
/
Hemorragia Pós-Operatória
Limite:
Humans
Idioma:
De
Revista:
Urologe A
Ano de publicação:
2013
Tipo de documento:
Article